Citius Pharmaceuticals, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$140M
↑+16.3% +$20Mvs FY2024
Total Liabilities
$47M
↓-9.4% -$5Mvs FY2024
Equity
$80M
↑+16.0% +$11Mvs FY2024
Cash
$8M
↑+601.9% +$7Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $140M | $121M |
| Current Assets | $38M | $18M |
| Cash | $8M | $1M |
| ST Investments | $0 | $0 |
| Receivables | $4M | $0 |
| Inventory | $23M | $14M |
| Other Current | $4M | $3M |
| Non-Current Assets | $102M | $102M |
| PPE | $0 | $0 |
| Goodwill | $9M | $9M |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $93M | $93M |
| Total Liab+Eq | $127M | $121M |
| Current Liab. | $38M | $45M |
| Accounts Payable | $11M | $7M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $27M | $37M |
| Non-Current Liab. | $9M | $7M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $9M | $7M |
| Equity | $80M | $69M |
| Retained Earnings | $247M | $211M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · CTXR · Comparing FY2025 vs FY2024